A novel PPARγ agonist, SP1818, shows different coactivator profile with rosiglitazone

Biomolecules and Therapeutics

Volumn 18, Issue 1, 2010, Pages 77-82

  Park, Yun Sun ^a   Choi, Jiwon ^a   Kim, Kun Yong ^a   Lim, Jong Seok ^a   Yoon, Sukjoon ^a   Yang, Young ^a  

^a Sookmyung Women's University   (South Korea)

Author keywords

Adipogenesis; Diabetes; Rosiglitazone

Indexed keywords

ADIPONECTIN; CD36 ANTIGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; SCAVENGER RECEPTOR; SP 1818; UNCLASSIFIED DRUG;

ADIPOCYTE; ARTICLE; CELL DIFFERENTIATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; TRANSACTIVATION;

EID: 76749094014     PISSN: 19769148     EISSN: None     Source Type: Journal    
DOI: 10.4062/biomolther.2010.18.1.077     Document Type: Article

References (21)

1. Auwerx, J. (1999). PPARgamma, the ultimate thrifty gene. Diabetologia 42, 1033-1049.
2. Berger, J. P., Akiyama, T. E. and Meinke, P. T. (2005). PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 26, 244-251.
3. Bhatia, V. and Viswanathan, P. (2006). Insulin resistance and PPAR insulin sensitizers. Curr. Opin. Investig. Drugs 7, 891-897.
4. Chao, L., Marcus-Samuels, B., Mason, M. M., Moitra, J., Vinson, C., Arioglu, E., Gavrilova, O. and Reitman, M. L. (2000). Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J. Clin. Invest. 106, 1221-1228.
5. Chiarelli, F. and Di Marzio, D. (2008). Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives. Vasc. Health Risk Manag. 4, 297-304.
6. Choi, J., Ko, Y., Lee, H. S., Park, Y. S., Yang, Y. and Yoon S. (2009) Identification of (β-carboxyethyl)-rhodanine derivatives exhibiting peroxisome proliferator-activated receptor γ activity (submitted).
7. Elsegood, C. L., Chang, M., Jessup, W., Scholz, G. M. and Hamilton, J. A. (2009). Glucose metabolism is required for oxidized LDL-induced macrophage survival: role of PI3K and Bcl-2 family proteins. Arterioscler. Thromb. Vasc. Biol. 29, 1283-1289.
8. Glass, C. K., Rose, D. W. and Rosenfeld, M. G. (1997). Nuclear receptor coactivators. Curr. Opin. Cell Biol. 9, 222-232.
9. Hauser, S., Adelmant, G., Sarraf, P., Wright, H. M., Mueller, E. and Spiegelman, B. M. (2000). Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. J. Biol. Chem. 275, 18527-18533.
10. Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M. and Kliewer, S. A. (1997). Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272, 3406-3410.
11. Liu, Q., Zhang, Y. Y., Lu, H. L., Li, Q. Y., Zhou, C. H. and Wang, M. W. (2007). Rhodanine derivatives as novel peroxisome proliferator-activated receptor gamma agonists. Acta. Pharmacol. Sin. 28, 2033-2039.
12. Mudaliar, S. and Henry, R. R. (2001). New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers. Ann. Rev. Med. 52, 239-257.
13. Nissen, S. E. and Wolski, K. (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471.
14. Olefsky, J. M. (2000). Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J. Clin. Invest. 106, 467-472.
15. Scheen, A. J. (2001). Thiazolidinediones and liver toxicity. Diabetes Metab. 27, 305-313.
16. Tolman, K. G. and Chandramouli, J. (2003). Hepatotoxicity of the thiazolidinediones. Clin. Liver Dis. 7, 369-379, vi.
17. Vidal-Puig, A., Jimenez-Linan, M., Lowell, B. B., Hamann, A., Hu, E., Spiegelman, B., Flier, J. S. and Moller, D. E. (1996). Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J. Clin. Invest. 97, 2553-2561.
18. Watkins, S. M., Reifsnyder, P. R., Pan, H. J., German, J. B. and Leiter, E. H. (2002). Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. J. Lipid Res. 43, 1809-1817.
19. Xu, H. E. and Li, Y. (2008). Ligand-dependent and -independent regulation of PPAR gamma and orphan nuclear receptors. Sci. Signal 1, pe52.
20. Zhu, Y., Qi, C., Korenberg, J. R., Chen, X. N., Noya, D., Rao, M. S. and Reddy, J. K. (1995). Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc. Nati. Acad. Sci. U S A 92, 7921-7925.
21. Zoete, V., Grosdidier, A. and Michielin, O. (2007). Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochimi. Biophys. Acta 1771, 915-925.